Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03XCR
|
|||
Former ID |
DIB005909
|
|||
Drug Name |
Simotaxel
|
|||
Synonyms |
MST-997; TL-909
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Taxolog Inc
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C46H57NO15S
|
|||
Canonical SMILES |
CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CS5)NC(=O)OC(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C7CCCC7
|
|||
InChI |
1S/C46H57NO15S/c1-23(2)58-42(55)47-33(29-18-13-19-63-29)34(50)41(54)59-28-21-46(56)38(61-40(53)27-14-9-8-10-15-27)36-44(7,30(49)20-31-45(36,22-57-31)62-25(4)48)37(51)35(32(24(28)3)43(46,5)6)60-39(52)26-16-11-12-17-26/h8-10,13-15,18-19,23,26,28,30-31,33-36,38,49-50,56H,11-12,16-17,20-22H2,1-7H3,(H,47,55)/t28-,30-,31+,33-,34+,35+,36-,38-,44+,45-,46+/m0/s1
|
|||
InChIKey |
SLGIWUWTSWJBQE-VLCCYYTCSA-N
|
|||
CAS Number |
CAS 791635-59-1
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin beta (TUBB) | Target Info | Inhibitor | [2] |
KEGG Pathway | Phagosome | |||
Gap junction | ||||
Pathogenic Escherichia coli infection | ||||
NetPath Pathway | FSH Signaling Pathway | |||
TCR Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Huntington disease | ||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
Loss of Nlp from mitotic centrosomes | ||||
Recruitment of mitotic centrosome proteins and complexes | ||||
Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
Anchoring of the basal body to the plasma membrane | ||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
Pathogenic Escherichia coli infection | ||||
Mitotic G2-G2/M phases |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00277836) Study Evaluating MST-997 in Advanced Malignant Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.